Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)
- 1 January 2009
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 4 (1) , 87-92
- https://doi.org/10.1097/jto.0b013e3181915052
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaBritish Journal of Haematology, 2008
- The Proteasome Inhibitor Bortezomib in Combination with Gemcitabine and Carboplatin in Advanced Non-small Cell Lung Cancer: A California Cancer Consortium Phase I StudyJournal of Thoracic Oncology, 2008
- Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- A prognostic model for advanced stage nonsmall cell lung cancerCancer, 2006
- Phase III Trial of Paclitaxel Plus Carboplatin With or Without Tirapazamine in Advanced Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial S0003Journal of Clinical Oncology, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806)Clinical Cancer Research, 2004
- Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trialLung Cancer, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976